Liberate Bio
Liberate’s RAPTOR delivery platform supports initial in vivo CAR-macrophage programs through monocyte/macrophage reprogramming. CAR-M is a neighboring modality, not CAR-T; these programs are not included in the confirmed CAR-T developer count.
Corporate information
- Company entity
- Liberate Bio
- Headquarters / principal office
- Boston, Massachusetts, United States ↗
- Founded
- 2022 ↗
- Ownership / capital status
- PrivateNot verified
- Official corporate reference
- https://www.liberatebio.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Liberate’s RAPTOR delivery platform supports initial in vivo CAR-macrophage programs through monocyte/macrophage reprogramming. CAR-M is a neighboring modality, not CAR-T; these programs are not included in the confirmed CAR-T developer count.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.